Mirna Therapeutics became Austin’s newest publicly traded company last week. The biopharmaceutical company, which is developing therapies for the treatment of liver cancer, filed an amended S-1 Registration document with the U.S. Securities Exchange Commission to offer 6.2 million shares at $7 a share to raise $44 million during its initial public offering last Thursday. […]